STERIS /$STE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About STERIS
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Ticker
$STE
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17,787
ISIN
IE00BFY8C754
Website
STERIS Metrics
BasicAdvanced
$23B
38.44
$6.21
0.94
$2.28
0.96%
Price and volume
Market cap
$23B
Beta
0.94
52-week high
$252.79
52-week low
$200.98
Average daily volume
621K
Dividend rate
$2.28
Financial strength
Current ratio
1.957
Quick ratio
1.189
Long term debt to equity
29.002
Total debt to equity
30.891
Dividend payout ratio (TTM)
35.77%
Interest coverage (TTM)
11.46%
Profitability
EBITDA (TTM)
1,254.708
Gross margin (TTM)
44.31%
Net profit margin (TTM)
11.26%
Operating margin (TTM)
18.10%
Effective tax rate (TTM)
23.19%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
5.78%
Return on equity (TTM)
9.46%
Valuation
Price to earnings (TTM)
38.438
Price to revenue (TTM)
4.307
Price to book
3.54
Price to tangible book (TTM)
35.89
Price to free cash flow (TTM)
30.223
Free cash flow yield (TTM)
3.31%
Free cash flow per share (TTM)
789.24%
Dividend yield (TTM)
0.96%
Forward dividend yield
0.96%
Growth
Revenue change (TTM)
6.24%
Earnings per share change (TTM)
63.01%
3-year revenue growth (CAGR)
8.93%
10-year revenue growth (CAGR)
11.48%
3-year earnings per share growth (CAGR)
35.82%
10-year earnings per share growth (CAGR)
10.68%
3-year dividend per share growth (CAGR)
9.68%
10-year dividend per share growth (CAGR)
9.50%
What the Analysts think about STERIS
Analyst ratings (Buy, Hold, Sell) for STERIS stock.
Bulls say / Bears say
STERIS' Healthcare segment reported a 9% year-over-year revenue increase in Q2 FY2025, driven by a 12% rise in consumable revenues and a 14% growth in service revenues, indicating strong demand for its products and services. (Zacks Investment Research)
The Applied Sterilization Technologies (AST) division experienced 9% reported growth year-over-year in Q2 FY2025, with a 6% increase in service revenues and significant improvement in capital equipment revenues, reflecting robust performance in this segment. (Zacks Investment Research)
Analysts have shown confidence in STERIS, with Piper Sandler upgrading the stock to 'Overweight' and raising the price target to $265, and Stephens maintaining an 'Overweight' rating with a $240 price target, suggesting positive market sentiment. (Defense World)
STERIS lowered its annual profit forecast due to a stronger dollar, which could impact international revenues and overall profitability. (Reuters)
Institutional investors like Allspring Global Investments Holdings LLC and SG Americas Securities LLC have reduced their positions in STERIS, potentially indicating concerns about the company's future performance. (Defense World, Defense World)
Despite revenue growth in certain segments, STERIS reported a 1.8% decline in total revenue in Q3 FY2025 compared to the same period last year, which may raise concerns about overall business momentum. (Finviz)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
STERIS Financial Performance
Revenues and expenses
STERIS Earnings Performance
Company profitability
STERIS News
AllArticlesVideos
U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report 2025-2030 Featuring STERIS, The Brewer Company, Midmark Corp. (Ritter Midmark), Clinton Industries, UMF Medical and More
GlobeNewsWire·1 month ago
Steris forecasts annual profit above estimates on strong medical equipment sales
Reuters·1 month ago
Steris Fiscal Fourth-Quarter 2025 Financial Results: Just the Numbers
Investopedia·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for STERIS stock?
STERIS (STE) has a market cap of $23B as of June 27, 2025.
What is the P/E ratio for STERIS stock?
The price to earnings (P/E) ratio for STERIS (STE) stock is 38.44 as of June 27, 2025.
Does STERIS stock pay dividends?
Yes, the STERIS (STE) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $2.28 and the yield is 0.96%. STERIS has a payout ratio of 35.77% on a trailing twelve-month basis.
When is the next STERIS dividend payment date?
The next STERIS (STE) dividend payment date is unconfirmed.
What is the beta indicator for STERIS ?
STERIS (STE) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.